RDHL
RedHill Biopharma Ltd.
$0.8100
-12.05%
$4.2M
No data for this timeframe.
Vol
Market Cap$4.2M
Cap SizeNano Cap
Inst. Holders4 funds
Inst. Value$19.2K
Inst. Activity1 buys / 0 sells
Insider Activity0B / 1S
Insider Net $-$1.6K
SEC Reports8
Recent Activity
Jun 9, 2026
SEC
RedHill Biopharma announced that the FDA granted Rare Pediatric Disease (RPD) designation to opaganib for neuroblastoma,
6-K — Impact 5/10
Jun 8, 2026
SEC
RedHill Biopharma filed a 6-K announcing it has commenced recognition and enforcement proceedings in Korea to collect a
6-K — Impact 5/10
Jun 2, 2026
SEC
RedHill Biopharma announced it is actively discussing potential collaborations to advance its investigational oral drug
6-K — Impact 4/10
Apr 6, 2026
Insider
Raday Gilead sold 15,740,000 shares
Chief Operating Officer @ $0.000100 ($1.6K)
Apr 6, 2026
Insider
Raday Gilead acquired via exercise 30,780,000 shares
Chief Operating Officer
Inst.
RHUMBLINE ADVISERS — ADD
5,116 shares ($3.8K)
Inst.
RHUMBLINE ADVISERS — ADD
2,678 shares ($2.8K)
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | ADD |
| CITADEL ADVISORS LLC | $15.4K | — |
| RHUMBLINE ADVISERS | $3.8K | ADD |
| MORGAN STANLEY | $1.00 | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 6, 2026 | Raday Gilead | SELL | $1.6K |
| Apr 6, 2026 | Raday Gilead | M | $0.00 |
4 institutional holders with $19.2K total value (25,791 shares) as of 2026-Q1. Top holders: ROYAL, CITADEL, RHUMBLINE. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 1 | $0.00 | 0.0% | ADD +33.3% |
| 2 | CITADEL ADVISORS LLC | 20,673 | $15.4K | 80.2% | — |
| 3 | RHUMBLINE ADVISERS | 5,116 | $3.8K | 19.8% | ADD +91.0% |
| 4 | MORGAN STANLEY | 1 | $1.00 | 0.0% | NEAR_EXIT -99.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | ADD | 2,678 | 5,116 | +91.0% | $3.8K | 2026-Q1 |
| RHUMBLINE ADVISERS | ADD | 1,768 | 2,678 | +51.5% | $2.8K | 2025-Q4 |
| GROUP ONE TRADING LLC | TRIM | 11 | 4 | -63.6% | $4.00 | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 7,988 | 23 | -99.7% | $50.00 | 2025-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 1,802 | 1 | -99.9% | $2.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 3 | 7,988 | +266166.7% | $15.5K | 2025-Q2 |
| RHUMBLINE ADVISERS | ADD | 1,388 | 1,768 | +27.4% | $3.4K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 2 | 303 | +15050.0% | $806.00 | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 2,213 | 13 | -99.4% | $34.00 | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 4,367 | 3 | -99.9% | $8.00 | 2025-Q1 |
| ROYAL BANK OF CANADA | ADD | 3 | 4 | +33.3% | — | 2024-Q4 |
| UBS Group AG | DOUBLED | 3 | 4,367 | +145466.7% | $27.1K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 180 | 2,213 | +1129.4% | $13.7K | 2024-Q4 |
1 unique insiders with 2 transactions. Net insider value: -$1.6K ($0.00 bought, $1.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 6, 2026 | Raday Gilead | Chief Operating Officer | SELL | 15,740,000 | $0.000100 | $1.6K |
| Apr 6, 2026 | Raday Gilead | Chief Operating Officer | EXERCISE | 30,780,000 | — | — |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 3 bearish, 2 mixed, 2 neutral. Avg impact: 5.5/10.
BULLISH
6-K
5/10
RedHill Biopharma announced that the FDA granted Rare Pediatric Disease (RPD) designation to opagani
Jun 9, 2026
MIXED
6-K
5/10
RedHill Biopharma filed a 6-K announcing it has commenced recognition and enforcement proceedings in
Jun 8, 2026
NEUTRAL
6-K
4/10
RedHill Biopharma announced it is actively discussing potential collaborations to advance its invest
Jun 2, 2026
BEARISH
6-K
6/10
RedHill Biopharma filed a 6-K on May 27, 2026, to report a May 7, 2026 prospectus supplement that in
May 27, 2026
BEARISH
20-F
8/10
RedHill Biopharma's 20-F filing confirms substantial doubt about its ability to continue as a going
Apr 27, 2026
MIXED
6-K
6/10
RedHill Biopharma reported its 2025 financial results, highlighting a strategic transformation throu
Apr 27, 2026
NEUTRAL
6-K
3/10
RedHill Biopharma announced new preclinical data showing opaganib's potential to enhance chemotherap
Apr 22, 2026
BEARISH
6-K
7/10
RedHill Biopharma received a Nasdaq deficiency notice due to its ADSs trading below $1.00 for 30 con
Apr 14, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2023-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2023-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Dec 1, 2024 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 17, 2026
Clinical Trial
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
Phase Phase 2 — COMPLETED